Retatrutide in Canada
Retatrutide is Eli Lilly's experimental weekly injection for obesity, the first to act on three hormone receptors at once. Canada has not approved it, and neither has anyone else. This site tracks where it stands, with a date and a source on every claim.
Retatrutide in Canada: what you need to know in 2026
Retatrutide is a triple hormone receptor agonist from Eli Lilly and Company, taken as a once-weekly injection under the skin. Semaglutide acts on one hormone receptor and tirzepatide on two. This one acts on three: GLP-1, GIP and glucagon. It has no brand name yet.
The big trials are in. In TRIUMPH-1, which followed 2,339 adults for 80 weeks, people on the 12 mg dose lost an average of 25.0% of their body weight, counting everyone who was randomized. People on placebo lost 3.9%. About 11 in every 100 on that dose stopped because of an adverse event.
Here is the catch for Canadians. No regulator has approved it, no submission sits with Health Canada, and the only firm timing is a US filing planned for the first quarter of 2027. That gap is what this site tracks: 11 events dated so far, 6 steps still ahead, and a source on each one.
What the retatrutide trials tested
Four phase 3 trials have reported, each in a different group of people. Read them together and you get a fair picture of how the drug behaves outside a single headline.
- TRIUMPH-1 2,339 adults. Obesity, in adults without diabetes. 25.0% average weight loss at 80 weeks on 12 mg counting everyone randomized, against 3.9% on placebo.
- TRIUMPH-2 1,152 adults. Obesity with type 2 diabetes. 18.8% average weight loss at 80 weeks on 12 mg counting everyone randomized, against 5.1% on placebo.
- TRIUMPH-3 1,949 adults. Obesity with cardiovascular disease. 22.6% average weight loss at 80 weeks on 12 mg in Lilly’s topline release, against 3.2% on placebo.
- TRIUMPH-4 445 adults. Obesity with knee osteoarthritis. 23.7% average weight loss at 68 weeks on 12 mg counting everyone randomized, against 4.6% on placebo.
Two of those are peer-reviewed and two are company results so far. The guide to what retatrutide is explains why each trial comes with two different weight-loss numbers, and which one this site quotes.
Retatrutide next to what Canada already has
| Drug | Sold as | Receptors | In Canada |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | One: GLP-1 | Authorized. Wegovy was cleared for weight management in 2021. |
| Tirzepatide | Mounjaro, Zepbound | Two: GLP-1 and GIP | Authorized. Zepbound was announced as available in July 2025. |
| Retatrutide | None yet | Three: GLP-1, GIP and glucagon | Not authorized. No submission under review. |
Each generation added a receptor. Whether the third one makes retatrutide better than tirzepatide is not settled, because the trial that compares them has not reported. Until it does, be wary of any chart that ranks the three.
Retatrutide price in Canada: why there is no number yet
You will find Canadian dollar figures for retatrutide online. Every one of them is invented. A drug gets a price when its maker launches it, and this one has not launched in any country. There is no US list price to convert and no Canadian one to quote.
What a vial costs on a peptide website is not a preview either. That is the price of an unverified product, set by whoever is selling it. When Eli Lilly announces a real price, it will appear on this site with the date and the source beside it.
If you want real numbers today, our sister site GLP-1 Costs Canada compares current Canadian pharmacy prices for the drugs that are approved here.
Why you cannot buy retatrutide in Canada
A drug has to be authorized before a pharmacy can stock it, and this one is not. That has not stopped a market from forming. Vials labelled retatrutide are sold on websites and social media, and Health Canada has named the drug in two public advisories about unauthorized peptides.
We do not list sellers, rank them or link to them. If you are weighing a purchase, read what is really for sale first. It covers the law, the border rules and a ten-second check that works on any medicine, whether you are looking at retatrutide or something else entirely.
Who writes this
Who is behind Retatrutide Canada
Each page is checked against Health Canada's records, the trial registry and the published papers, and carries the date of that check. Pages that make clinical claims say plainly whether a pharmacist has reviewed them yet.
Retatrutide Canada Editorial TeamEditorial
We track retatrutide through Health Canada, the FDA, the trial registry and the medical journals, and write up what those records say. Each claim on this site carries a date and a source, and we do not publish a Canadian price or an approval date that no regulator has published. The site takes no manufacturer funding, has no affiliation with Eli Lilly, and links to no seller of retatrutide.
Three signals that would change this page
- A Canadian submission. Health Canada lists each new drug it accepts for review. Retatrutide showing up there is the first real sign of movement.
- The FDA filing. Lilly has stated a window of the first quarter of 2027. A stated window is not a date.
- The head-to-head result. TRIUMPH-5 compares retatrutide with tirzepatide. The registry estimates its main data collection ends in November 2026.
Latest retatrutide news for Canada, by date
- TRIUMPH-1 and TRIUMPH-2 published in journals
- Lilly Canada warns about black-market retatrutide
- Lilly sets out its filing plan
- Lilly opens case-by-case early access
- TRIUMPH-2 and TRIUMPH-3 report
Those are the five most recent dated events. The full timeline has every entry with its source, plus the steps that have not happened yet.
Who this retatrutide site is for
Three kinds of reader land here. Some saw a trial headline and want to know if their doctor can prescribe it. Some are on Ozempic, Wegovy, Mounjaro or Zepbound and wonder whether to wait for something stronger. And some have seen vials for sale and want to know what they would be getting into.
I wrote the guides for all three, and I tried to answer the question you came with in the first paragraph of each page. If you only read one, make it the one that matches your situation. None of them will tell you what to take. That decision belongs with a prescriber who knows your history. What we can do is make sure you walk into that appointment with the facts straight and the hype left at the door.
How Retatrutide Canada checks its facts
Health information about an unapproved drug is easy to get wrong, and a lot of what ranks for this topic was written to sell something. So here are our rules. Health Canada's records decide what we say about status. Where a trial has been published in a journal, we quote the journal ahead of the press release. When a number comes only from the company, the page says so.
Pages that make clinical claims carry a notice until a licensed Canadian pharmacist has reviewed them. No page here shows a review credit it has not earned. The details are in our editorial policy.
Every retatrutide guide on this site
The retatrutide approval timeline
Every dated step so far, and each one left before a Canadian pharmacy could fill a prescription.
Read more →
Is retatrutide available in Canada?
Where it stands with Health Canada, the 10 trials with Canadian sites, and what is authorized today.
Read more →
Buying retatrutide in Canada
No lawful seller exists. What is really inside the vials offered online, and where the law draws the line.
Read more →
Retatrutide side effects by dose
Reported rates from four phase 3 trials, how many people stopped, and the skin-sensation finding.
Read more →
Retatrutide dosage in the trials
The weekly doses tested, what each step added, and how slowly the trials stepped people up.
Read more →
The retatrutide peptide
A 39-link chain built to last a week, and why the vials sold online under its name are a different matter.
Read more →
What is retatrutide?
How a triple agonist works, how it differs from Ozempic and Mounjaro, and what is still unproven.
Read more →Retatrutide Canada: frequently asked questions
Can I get retatrutide in Canada right now?
Not from a doctor or a pharmacy. Health Canada has not authorized it, so it cannot be prescribed or dispensed. The lawful exceptions are clinical trials and, rarely, a doctor’s Special Access request that Lilly agrees to supply. Both have narrow entry rules.
When is retatrutide coming to Canada?
Nobody has published a date. Eli Lilly plans a US filing in the first quarter of 2027 and has not announced a Canadian one. Health Canada’s review targets add up to most of a year after a filing, so the wait is long.
How much weight did people lose in the retatrutide trials?
In the largest trial, an average of 25.0% of body weight at 80 weeks on the top dose, counting everyone randomized. Company press releases quote a higher figure that assumes people stay on treatment.
What are the usual retatrutide side effects?
Nausea, diarrhea, constipation and vomiting lead the list, as they do for related drugs. The trials also recorded an abnormal skin sensation called dysesthesia.
What will retatrutide cost in Canada?
Nobody knows. It is not on sale in any country, so no price exists to quote. A Canadian price appears only after Health Canada authorizes a drug and the company launches it.
Should I wait for retatrutide or start an approved drug now?
That is a decision for you and a prescriber, and this site cannot make it. What we can say is that the wait is likely to be measured in years, and that no trial has yet shown retatrutide beating the approved drugs head to head.
Are Canadians in the retatrutide trials?
Yes. 10 registered retatrutide trials have listed study sites in Canada, and most are finished or closed to new participants.
Is retatrutide the same as Ozempic or Mounjaro?
No. Ozempic is semaglutide and Mounjaro is tirzepatide. Retatrutide is a newer drug in the same family that switches on a third hormone receptor. It comes from Eli Lilly, the maker of Mounjaro.
Is retatrutide a pill or an injection?
An injection, taken once a week in every trial so far. No pill version has been tested in the phase 3 programme.
How often is this site updated?
Whenever a regulator, a journal or Eli Lilly publishes something that changes a fact here. Each page shows the date it was last checked, so you can judge how fresh it is for yourself.
Who is behind this site?
It is independent. It has no affiliation with Eli Lilly, takes no manufacturer money, sells nothing, and links to no seller of retatrutide. Nothing on it is advice to obtain an unapproved medicine.